A multi-site Phase 1 study to evaluate its safety and anti-tumor activity of TIDAL-01 in patients with advanced solid tumors including breast cancer and colorectal cancer
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs TIDAL-01 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Uveal melanoma
- Focus Adverse reactions
- Acronyms STARLING
- 04 Feb 2025 Status changed from planning to discontinued.
- 01 Sep 2023 According to a Turnstone Biologics media release, company expects to provide an initial clinical update in mid-2024.
- 11 Nov 2022 New trial record